ArticleJournal of inflammation research2026
PD-1/TIGIT CD4⁺ T-Cell Signature for Risk Stratification of Post-Weaning Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mortality after successful weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains common, yet few immune biomarkers enable post-weaning risk stratification. We examined whether circulating CD4⁺ T-cell subsets defined by programmed cell death protein 1 (PD-1) and T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) were associated with off-ECMO mortality in adults supported with VA-ECMO. Methods: We conducted flow cytometric profiling of circulating T cells in 125 adult VA-ECMO patients, classified as survivors (n = 70), on-ECMO mortality (n = 33), and off-ECMO mortality after successful weaning (n = 22). We first quantified CD3⁺, CD4⁺, and CD8⁺ T-cell counts using BD Trucount tubes, and assessed conventional CD4⁺ and CD8⁺ differentiation subsets by flow cytometry. We then quantified PD-1/TIGIT-defined CD4⁺ T cell subsets and assessed their ability to discriminate off-ECMO mortality among successfully weaned patients using receiver operating characteristic (ROC) analyses with bootstrap resampling. A PD-1/TIGIT-based risk classification was constructed using ROC-derived cut-offs. Results: Although CD3⁺/CD4⁺/CD8⁺ T-cell counts and conventional CD4⁺ differentiation subsets did not differ across outcome groups, the off-ECMO mortality group showed a higher frequency of CD4⁺PD-1 Conclusion: A circulating CD4⁺ T cell signature defined by PD-1 and TIGIT expression associates with off-ECMO mortality and may aid risk stratification after VA-ECMO weaning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.